Change of Auditor

About this update from Cambridge Cognition Holdings Plc

5 November 2025   Cambridge Cognition Holdings plc   ("Cambridge Cognition", the "Company" or the "Group")   Change of Auditor   Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces the appointment of Cooper Parry Group Limited ("Cooper Parry") as the Company's new external auditor following a competitive audit tender process.  The Company also announces that as a result of the process Crowe UK LLP ("Crowe") has resigned as the Company's auditor.   Cooper Parry will conduct the audit of the Company's financial statements for the financial period to 31 December 2025 and a proposal to re-appoint Cooper Parry as auditors of the Company will be subject to the approval of shareholders at the 2026 Annual General Meeting.   Crowe has been the auditor for the Company since 2023. Crowe has confirmed to the Company that there are no matters connected with their ceasing to hold office that need to be brought to the attention of the members or creditors of the Company for the purposes of section 519 of the Companies Act 2006.   Enquiries:   Cambridge Cognition Holdings plc   Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer   Tel: 01223 810700  [email protected]   Panmure Liberum Limited (NOMAD and Joint Broker) Will Goode / Mark Rogers / Freddy Crossley Rupert Dearden   Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking)   Dowgate Capital Limited (Joint Broker)  David Poutney / Amber Higgs   Tel: 020 3903 7715        Notes to Editors About Cambridge Cognition Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment. Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  The Company has identified four market sectors: ·    Clinical Studies  for new pharmaceuticals; ·    Academic Research  for scientists to understand CNS disorders; ·    Healthcare  to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and, ·    Consumer Health & Wellness  to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. For further information, visit:  www.cambridgecognition.com    

View stock analysis, news, and events for Cambridge Cognition Holdings Plc